Biolojic Design Overview
Biolojic Design is a biopharmaceutical company dedicated to the development of human antibody-based therapeutics for cancer and other diseases. Biolojic Design has developed a new tool to re-engineer antibodies to bind new epitopes in a process known as re-epitoping. This technology has been shown to yield functional antibodies in difficult targets. Using proprietary algorithms, the company identifies an existing antibody that can be re-epitoped to bind the desired target. The antibody template is then engineered in an iterative computational and experimental approach to bind the desired epitope with high affinity. In 2014, Biolojic partnered with AstraZeneca's MedImmune LLC Biologics unit to discover antibodies for undisclosed targets selected by MedImmune, using Biolojic's computational and biochemical tools.
Cumulative Funding Raised Over Time ($)
Latest News
growth-positive
Biolojic Design lands drug discovery collaboration with Merck potentially worth up to 346 million euros | CTech
Israeli biotech firm Biolojic Design has entered into a collaboration agreement with pharmaceutical giant Merck, potentially worth up to €346 million. The partnership will leverage Biolojic Design’s AI-driven discovery platform to design therapeutic antibodies for the treatment of cancer and immunological disorders. In the first phase, Biolojic Design will receive slightly more than €10 million for the development of two molecules that could serve as the basis for drugs targeting cancer and several immunological disorders. The company will receive additional funding as development progresses, with the full amount contingent on the drug reaching the market and generating sales.
PartnersInvestment
growth-positive
Teva buys rights for Israeli co Biolojic's asthma treatment
Teva Pharmaceutical Industries and Biolojic Design have entered into a collaboration agreement for the development of an antibody-based therapy for asthma and atopic dermatitis. As part of the agreement, Teva will make an upfront payment and milestone payments to Biolojic. Biolojic is also eligible to receive tiered royalties in the millions of dollars on product sales if Teva successfully commercializes the therapy. The drug is currently in animal trials.
PartnersInvestment
growth-positive
Biolojic Design Appoints Ronald Herbst, Ph.D., as Chief Scientific Officer
Biolojic Design has appointed Ronald Herbst, Ph.D. as Chief Scientific Officer. Dr. Herbst brings extensive experience in the biopharmaceutical industry and will play a key role in expanding the companys U.S. operations and advancing computationally designed smart antibodies into the clinic. The appointment demonstrates the companys commitment to delivering smart therapeutics to patients. Dr. Herbsts expertise in cancer and immunology and his track record in drug development will contribute to the companys vision of revolutionizing the treatment of cancer and immunological diseases. Biolojic Design is focused on designing and developing a pipeline of revolutionary therapeutics using AI technology. The company aims to unlock the full potential of well-studied pathways in cancer and autoimmune diseases.
Management Changes
growth-positive
The Logical Song: Biolojic Design Reimagines Antibodies into "Smart" Therapeutics
Biolojic Design, a technology company based in Tel Aviv and Boston, is using computational design and AI technology to transform antibodies into intelligent medicinal solutions. The company aims to offer therapies for various diseases, with a focus on cancer and autoimmune illnesses. In April 2022, Biolojic announced that an antibody designed using its AI technology entered a clinical trial, making it the first computationally designed antibody to be tested in humans. The antibody, AU-007, is being developed by Aulos Bioscience, a Biolojic spinoff founded with $40 million in Series A funding from ATP. Biolojic Design is working on a pipeline of antibodies with novel therapeutic properties and is focused on building its own revolutionary antibodies for clinical development.
InvestmentPartners
growth-positive
Made in Israel: First AI-designed antibody could lead to eradication of tumors
Biolojic Design, an Israeli biotech company, is conducting clinical trials in Australia for its computer-designed antibody, AU-007, which is aimed at treating terminal cancer. The antibody is designed to activate a molecule known as IL-2, which can eradicate tumors. The trials have shown positive results in mice, leading to the complete elimination of tumors in over half of the subjects. The company has raised about $30 million from investors including aMoon, Keter Plastics, and Prof. Chezy Barenholz. It also co-founded a new company, Aulos Bioscience, with venture capital firm Apple Tree Partners, which invested $40 million to advance AU-007.
InvestmentPartners
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $3.95M |
| Last funding | $7.5M |
| Stage | Seed |
| Rounds | 3 |
| Investors | 4 |
Team Members
5
Employees: 51-200
Web & Social Links
| Website | biolojic.com |
| Careers | Careers page |
Locations
HaMada St 12, Rehovot, Israel
Boston, MA, USA
Photos & Videos
1 item(s)
